W.D. Tex. Court Finds Kimble Inapplicable to Royalties Based on a Foreign Patent; Enforces License

Jan 30, 2018

Reading Time : 3 min

The parties, Nautilus, Inc. (“Nautilus”) and Icon Health & Fitness, Inc. (“Icon”), are both exercise-equipment companies. Nautilus gave Icon a license to use its U.S. and foreign patented technology in Icon’s elliptical machines. In the agreement, Icon received a nonexclusive license in exchange for a five-percent royalty on gross sales of “Products” (elliptical machines that fall within the scope of one or more licensed patents). On January 25, 2015, all of the patents licensed under the license had expired except for one—Nautilus’s Chinese patent. Icon made some payments after the January 2015 expiration date, but ultimately took the position that its devices that were manufactured and partially assembled in China were not “Products” under the license. Nautilus sued to enforce the license. This teed up the issue that touched on the Supreme Court’s 2015 decision in Kimble v. Marvel Entm’t. LLC, 135 S. Ct. 2401, 2415 (2015): Could the court enforce royalties owed on “Products” that were imported into the United States after the expiration of a U.S. patent, but made in China under a nonexpired Chinese patent?

Before analyzing royalties, the court had to determine whether the products actually infringed the Chinese patent under Chinese law, as was required by the license agreement. The Chinese patent covered the final assembled product— the individual components and the structural relationships between them—but, Icon manufactured unassembled machines that were subsequently assembled in the United States by customers using a provided instruction manual. The court ruled that, under Chinese law providing the instruction manual was equivalent to providing the structural relationship between the parts. This meant that the devices infringed under Chinese law and, accordingly, were “Products” covered by the parties’ license.

Turning to the royalty issue, the court examined whether the royalty provision was enforceable when only the Chinese patent remained in effect. Brulotte v. Thys Co., which was recently upheld in Kimble, holds that contracts requiring the payment of royalties after the expiration of a U.S. patent are unenforceable. 379 U.S. 29, 32 (1964). Although the court observed that the Brulotte rule was a “bad rule,” the court acknowledged that it was bound to apply it and that the rule had recently been affirmed by Kimble on stare decisis grounds. As the court observed, however, Brulotte and Kimble still allow a licensor to contract for royalties post-expiration of its U.S. patents if the post-expiration royalties are tied to some separate right that exists independently of the expired patent. According to the court’s reasoning, such a separate, independent right could be provided by another unexpired patent.

The court looked to the 9th Circuit’s analysis in Zila, Inc. v. Tinnell, which the court found to be a “substantially similar” case. 502 F.3d 1014 (9th Cir. 2007). The Zila court found enforceable a royalty provision after the expiration of the licensed U.S. patents where a licensed Canadian patent was still in effect. It reasoned that Brulotte does not “[E]xtend its royalty-canceling powers to contracts for foreign patents . . . . Even if the principle announced in Brulotte were to obviate Zila’s obligation to pay royalties on the [American] patent once it expired, . . . it [does not] displace[] Zila’s obligation to pay royalties on the valid Canadian patent.” Id. at 1023-24.

Judge Lamberth “wholly agreed” with the Zila decision, and, accordingly, Nautilus prevailed. The court proceeded to find that the total damages owed was “at least $1,782,508,” including interest. Finally, the court found that, under the license, Nautilus was entitled to attorney’s fees.

Nautilus, Inc. v. Icon Health & Fitness, Inc., No. SA-16-CV-00080-RCL, 2018 U.S. Dist. LEXIS 9828 (W.D. Tex. Jan. 19, 2018)

Share This Insight

Categories

Previous Entries

IP Newsflash

November 14, 2025

The Ninth Circuit recently reversed a district court’s decision to strike a plaintiff’s trade secret claims under the Defend Trade Secrets Act (DTSA) at the discovery stage. In doing so, the Ninth Circuit made clear that under the DTSA, whether a party defined their trade secret with sufficient particularity is a question of fact that generally does not lend itself to resolution in the absence of at least some discovery. This ruling contrasts with the California Uniform Trade Secrets Act (CUTSA), which requires a party to define their trade secrets with reasonable particularity before commencing discovery.

...

Read More

IP Newsflash

November 11, 2025

The Federal Circuit recently vacated a summary judgment ruling of invalidity, holding that the district court erred in applying preclusive effect to the Patent Trial and Appeal Board’s unpatentability findings regarding other claims in the same patent. In doing so, the Federal Circuit reiterated that issue preclusion does not apply where the prior factual determinations were made under a lower standard of proof.

...

Read More

IP Newsflash

November 3, 2025

The Federal Circuit recently clarified the requirement for work disclosed in a reference to qualify as “by another” under pre-AIA Sections 102(a) and (e), holding that there must be complete inventive identity between the information disclosed in the asserted reference and the inventors named on the relevant patent. 

...

Read More

IP Newsflash

October 31, 2025

The District Court for the Northern District of California recently granted a defendant’s motion to bifurcate, ordering that issues related to PGR estoppel should be decided in a bench trial, while the remaining issues in the case should proceed to a jury trial.

...

Read More

IP Newsflash

October 31, 2025

The Northern District of Iowa recently held that a defendant’s motion for partial summary judgment of invalidity was barred after the PTAB issued final written decisions, regardless of when the motion was filed. The defendant filed its motion before the final written decisions were issued, but the court rejected the defendant’s argument that the timing of the motion insulated it from estoppel.

...

Read More

IP Newsflash

October 1, 2025

In a recent final written decision, the PTAB determined that a reference patent was not prior art, despite the petitioner’s post‑filing attempt to correct its petition. While the petitioner argued that it intended to rely on the patent application’s earlier date of publication, both the corrected petition and the expert declaration continued to reference the issued patent rather than the published application.

...

Read More

IP Newsflash

September 30, 2025

The USPTO Director recently granted a petitioner’s request for rehearing of the decision discretionarily denying institution of inter partes review, ultimately vacating the original decision, and referring the petition to the board for an institution decision.

...

Read More

IP Newsflash

September 25, 2025

In considering claims to a method of reducing cardiovascular events, the Federal Circuit held that the term a “clinically proven effective” amount did not render the claims patentable over the prior art. Specifically, the Federal Circuit held that the “clinically proven effective” amount, whether limiting or not, could not be used to distinguish the prior art because the claims also specified the exact amount of the drugs to be administered in the method. The Federal Circuit also rejected patentee’s evidence of unexpected results because that evidence was tied solely to the “clinically proven effective” limitation.

...

Read More

© 2025 Akin Gump Strauss Hauer & Feld LLP. All rights reserved. Attorney advertising. This document is distributed for informational use only; it does not constitute legal advice and should not be used as such. Prior results do not guarantee a similar outcome. Akin is the practicing name of Akin Gump LLP, a New York limited liability partnership authorized and regulated by the Solicitors Regulation Authority under number 267321. A list of the partners is available for inspection at Eighth Floor, Ten Bishops Square, London E1 6EG. For more information about Akin Gump LLP, Akin Gump Strauss Hauer & Feld LLP and other associated entities under which the Akin Gump network operates worldwide, please see our Legal Notices page.